News
OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- Omega Therapeutics, Inc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback